- Supported exchanges /
- TWO /
- 6885.TWO
BRIM Biotechnology Inc. (6885 TWO) stock market data APIs
BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company's lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing BRM 423 to treat severe corneal damage, which is in phase 1 clinical trial; BRM 424 for the treatment of neurotrophic keratitis, which is in phase 1 clinical trial; and BRM 521 to relieve and repair tissue damage caused by osteoarthritis. The company was founded in 2013 and is based in Taipei, Taiwan.
BRIM Biotechnology Inc. Financial Data Overview
| 43.45 | |
| 43.5 | |
| - | |
| 43.6 | |
| 42.6 | |
| 24.6-80.5 | |
| 5 030 M | |
| 116 M | |
| 90 000 | |
| 1.167 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
BRIM Biotechnology Inc. Fundamental Data is available in our Financial Data APIs
- Net Revenue 90 000
- EBITDA -690 956 992
- Earnings Per Share -6.26
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get BRIM Biotechnology Inc. Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get BRIM Biotechnology Inc. End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
